HS-10374 / Jiangsu Hansoh Pharma - LARVOL DELTA

A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis (clinicaltrials.gov) - P2 | N=305 | Not yet recruiting | Sponsor: Hansoh BioMedical R&D Company

New P2 trial • Dermatology • Immunology • Psoriasis

A multicenter, randomized, double-blind, placebo-controlled Phase III study evaluating the efficacy and safety of HS-10374 tablets in adults with moderate-to-severe plaque psoriasis (ChiCTR) - P3 | N=375 | Sponsor: Huashan Hospital, Fudan University; Huashan Hospital, Fudan University

New P3 trial • Dermatology • Immunology • Psoriasis

A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P3 | N=375 | Not yet recruiting | Sponsor: Hansoh BioMedical R&D Company

New P3 trial • Dermatology • Immunology • Psoriasis

EADV 2024 | Hansoh Pharma Released the Phase II Clinical Study Data of HS-10374，in Patients with Moderate-to-Severe Plaque Psoriasis (Hansoh Pharma Press Release) - P2 | N=120 | NCT06077331 | Sponsor: Hansoh BioMedical R&D Company | "The 33rd Annual Congress of the European Academy of Dermatology and Venereology (EADV 2024) was held in Amsterdam from September 25 to 28, 2024. The Phase II clinical trial data for Hansoh Pharma 's HS-10374 on plaque psoriasis were presented at the congress....Efficacy (data at Week 12): The primary endpoint was met, with a significantly greater proportion of patients in HS-10374 6 mg and 12 mg groups achieving PASI 75 responses compared with PBO (PBO: 7.5%; HS-10374 6 mg: 28.6%, P=0.013; HS-10374 12 mg: 72.1%, P<0.001). Significantly greater proportion of patients in HS-10374 6 mg and 12 mg groups achieved sPGA 0/1 responses compared with PBO as well (PBO: 10.0%; HS-10374 6 mg: 33.3%, P<0.05; HS-10374 12 mg: 65.1%, P<0.001)."

P2 data • Psoriasis

Efficacy and safety of HS-10374 in patients with moderate-to-severe plaque psoriasis: Results from a randomized, double-blind, placebo-controlled phase 2 trial (EADV 2024) - P2 | "HS-10374 showed significant clinical efficacy versus PBO in PASI 75 response rate and sPGA 0/1 response rate at oral doses ≥ 6 mg in patients with moderate-to-severe plaque psoriasis. The overall safety profile was similar to other TYK2 inhibitors with less risk of skin toxicity. Trials of longer treatment duration with a larger population are required to further confirm the efficacy and safety of HS-10374 in such patients."

Clinical • Late-breaking abstract • P2 data • Dermatology • Gastrointestinal Disorder • Immunology • Infectious Disease • Psoriasis • IL23A • TYK2

Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis (clinicaltrials.gov) - P2 | N=160 | Recruiting | Sponsor: Hansoh BioMedical R&D Company | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis (clinicaltrials.gov) - P2 | N=160 | Not yet recruiting | Sponsor: Hansoh BioMedical R&D Company

New P2 trial • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Hansoh BioMedical R&D Company | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Immunology • Psoriasis

A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Hansoh BioMedical R&D Company

New P2 trial • Dermatology • Immunology • Psoriasis • CRP

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects (clinicaltrials.gov) - P1 | N=84 | Completed | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

New P1 trial • Dermatology • Immunology • Psoriasis • CRP • CST3